| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6fda8060b9b2e685a6a068b85203c7ed |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2018-10-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c56f9c19c782bef1d8aba5ea1853c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2bd2549576345b77e0ac1730415da8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_435dedb22e403d802592060d3e4193fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02f6497c2e52f6e3cefe2323cf6727cb |
| publicationDate |
2019-04-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2019055954-A |
| titleOfInvention |
Temporary protection of normal cells during chemotherapy |
| abstract |
The present invention provides a method for reducing the effect of a chemotherapeutic agent on normal cells of a subject undergoing treatment for cyclin dependent kinase 4/6 (CDK 4/6) replication independent cancer or abnormal cell growth. A method of reducing the effect of a chemotherapeutic agent using the compounds exemplified below. [Selected figure] Figure 6B |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7213854-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021001197-A |
| priorityDate |
2013-03-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |